Study of Pembrolizumab (MK-3475) Subcutaneous (SC) Versus Pembrolizumab Intravenous (IV) Administered With Platinum Doublet Chemotherapy in Participants With Metastatic Squamous or Nonsquamous Non-Small Cell Lung Cancer (NSCLC) (MK-3475-A86)

NCT04956692 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

531

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-Small Cell Lung Cancer

Interventions

BIOLOGICAL: Pembrolizumab SC
BIOLOGICAL: Pembrolizumab IV
DRUG: Paclitaxel
DRUG: Nab-Paclitaxel
DRUG: Carboplatin
DRUG: Cisplatin
DRUG: Pemetrexed

Sponsor

Merck Sharp & Dohme LLC